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Summary
 
The molecular mechanisms underlying target recognition during natural killing are not well
understood. One approach to dissect the complexities of natural killer (NK) cell recognition is
through exploitation of genetic differences among inbred mouse strains. In this study, we de-
termined that interleukin 2–activated BALB/c-derived NK cells could not lyse Chinese ham-
ster ovary (CHO) cells as efficiently as C57BL/6-derived NK cells, despite equivalent capacity
to kill other targets. This strain-determined difference was also exhibited by freshly isolated NK
cells, and was determined to be independent of host major histocompatibility haplotype. Fur-
thermore, CHO killing did not correlate with expression of NK1.1 or 2B4 activation mole-
cules. Genetic mapping studies revealed linkage between the locus influencing CHO killing,
termed 
 
Chok
 
, and loci encoded within the NK gene complex (NKC), suggesting that 
 
Chok
 
 en-
codes an NK cell receptor specific for CHO cells. In vivo assays recapitulated the in vitro data,
and both studies determined that 
 
Chok
 
 regulates an NK perforin–dependent cytotoxic process.
These results may have implications for the role of NK cells in xenograft rejection. Our genetic
analysis suggests 
 
Chok
 
 is a single locus that affects NK cell–mediated cytotoxicity similar to
other NKC loci that also regulate the complex activity of NK cells.
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N
 
atural killer (NK) cells are bone marrow–derived
lymphocytes, distinct from T and B cells, that are
capable of lysing certain tumor cells without prior sensitiza-
tion (1, 2). Because of this capacity, termed natural killing,
NK cells serve as a first line of defense against certain intra-
cellular pathogens and perhaps developing tumor cells (3,
4). Although the phenomenon of natural killing has been
studied intensely for many years and underlies the func-
tional definition of NK cells, the molecular mechanisms
underlying target recognition during natural killing are not
well understood. Despite some descriptions of natural kill-
ing as being nonspecific, it is not random. In general, NK
cells do not lyse normally dividing cells, and their suscepti-
ble targets are classically tumor cell lines, among which
there is marked differential sensitivity (5). NK cells do not
rearrange T cell antigen receptor genes nor do they express
surface Ig (6). Therefore, NK cells must possess a recogni-
tion mechanism to discriminate between appropriate tar-
gets and normal cells that is distinct from the antigen-spe-
cific receptors of T and B cells.
Recent studies on the inverse correlation between target
cell expression of MHC class I and target cell susceptibility
to NK cell lysis have provided major insight into NK cell
recognition. In the “missing-self hypothesis,” Kärre postu-
lated that NK cells are chronically inhibited by MHC class
I. Accordingly, if a cell lacks expression of MHC class I or
expresses an aberrant form, the inhibitory influence is lost,
permitting the NK cell to lyse the target (7–9). The identi-
fication of MHC class I–specific inhibitory receptors in ro-
dents (Ly-49) and humans (killer cell inhibitory receptor
[KIR]
 
1
 
 and CD94/NKG2) provides a molecular basis for
this hypothesis. Receptors in all three of these families con-
tain immunoreceptor tyrosine-based inhibitory motifs (IT-
IMs) in their cytoplasmic domain, which have been shown
 
1
 
Abbreviations used in this paper:
 
 B6, C57BL/6; CHO, Chinese hamster
ovary; AGM1, asialo ganglio-
 
N
 
-tetraosylceramide; ITIM, immuno-
receptor tyrosine-based inhibitory motif; KIR, killer inhibitory receptor;
MCMV, murine cytomegalovirus; NKC, NK gene complex; RI, re-
combinant inbred; SDP, strain distribution pattern.
  
2244
 
Genetic Control of NK Cells by 
 
Chok
 
to recruit cytoplasmic tyrosine phosphatases like SHP-1
upon receptor cross-linking and subsequent ITIM phos-
phorylation (10–15). Therefore, these MHC class I–specific
inhibitory receptors on NK cells may explain the original
observations regarding the inverse relationship between
target cell expression of MHC class I and susceptibility to
lysis that led to Kärre’s hypothesis.
However, the known inhibitory receptors do not ex-
plain all aspects of NK cell specificity. For example, mouse
NK cell clones have varying reactivity against a panel of tu-
mor targets yet do not express members of the Ly-49 fam-
ily (16). Moreover, in addition to the inhibitory receptors,
NK cell recognition appears to involve activation recep-
tors, giving rise to a two-receptor model for NK cell acti-
vation. This model predicts that the fate of a target cell is
determined by the integration of signals transduced by in-
hibitory and activation receptors which are simultaneously
expressed on a single NK cell (17, 18). Studies using mAbs
specific for NK cell surface structures have led to the de-
scription of candidate activation receptors. Cross-linking
these receptors with specific mAbs stimulates NK cells to
kill targets that are otherwise inefficiently lysed. In rodents,
these molecules include NKR-P1, CD69, Ly-6, 2B4, and
Ly-49D (19–22). Although mAbs have helped identify
candidate receptors, the role of these molecules in natural
killing and in in vivo NK cell function remains unclear.
Recent studies by Ryan et al. took a mutagenesis ap-
proach in order to define the role of NKR-P1A in natural
killing. An NKR-P1–deficient mutant of the rat RNK-16
line demonstrated natural killing of YAC-1 cells but not
other mouse tumor targets (23). Transfection of the mutant
RNK cells with rat NKR-P1A restored lysis of only the
xenogeneic IC-21 target. Although these studies strongly
suggest that NKR-P1A molecules are target-specific recep-
tors that activate natural killing, the NKR-P1–deficient
NK clones were able to lyse other targets, suggesting other
routes for activation of natural killing. Hence, there must
be other receptors, perhaps some yet to be described, that
can influence NK cell recognition.
The current panoply of NK cell receptors is further
complicated by the expression of multiple receptors on an
individual NK cell and on overlapping NK cell subsets.
The resultant heterogeneic NK cell receptor repertoire
renders it difficult to analyze the contribution of individual
receptors in natural killing. One approach to dissect the
complexities of NK cell recognition is to exploit genetic
differences among inbred strains of mice. Additionally, the
availability of recombinant inbred and congenic strains of
mice as well as the current wealth of informative genetic
markers makes it possible to rapidly identify novel loci con-
trolling NK cell function.
In the present study, we demonstrate that NK cells from
two distinct inbred mouse strains possess differential cyto-
toxic capacity against Chinese hamster ovary (CHO) target
cells. This is an intrinsic phenomenon, manifested in freshly
isolated NK cells as well. We have exploited this differen-
tial cytotoxicity to identify a genetic locus, termed 
 
Chok
 
,
responsible for NK cell–mediated cytotoxicity of tumor
 
cells. This locus is linked to the NK gene complex (NKC),
and also influences the capacity to clear tumor cells in vivo
through a perforin-dependent mechanism, consistent with
the hypothesis that 
 
Chok
 
 encodes a recognition structure
specific for certain targets.
 
Materials and Methods
 
Mice.
 
All mouse strains, except the BALB.B6-
 
Cmv1
 
r
 
,
B6.BALB-
 
Cmv1
 
s
 
, and the intra-NKC recombinant strains, were
obtained from The Jackson Laboratory (Bar Harbor, ME), in-
cluding C57BL/6J (B6), BALB/cJ, C57BL/6ByJ, BALB/cByJ,
CB6F1/J, C57BL10/J, B10.D2, BALB.B, NZB/B1NJ, NZW/
LacJ, NOD/LtJ, DBA/2J, 129/J, C3HeB/FeJ, AKR/J, A/J, SJL/
J, ST/J, CE/J, C57L/J, C57BR/cdJ, C58/J, C57BL/6-
 
Pfp
 
tm1Sdz
 
,
and seven mice of the recombinant inbred panel derived from
C57BL/6ByJ and BALB/cByJ parental strains, CXB-1 through -7.
The BALB.B6-
 
Cmv1
 
r
 
 mouse is a congenic strain in which the
murine cytomegalovirus (MCMV) resistance allele,
 
 Cmv1
 
r
 
, as
well as other NKC-linked loci from C57BL/6J strain have been
transferred onto the BALB/c genetic background as described
previously (24). The B6.BALB-
 
Cmv1
 
s
 
 congenic strain supports
high splenic MCMV titers since it carries the susceptible BALB/c
allele, 
 
Cmv1
 
s
 
 (25). This strain also contains other BALB/c-derived
NKC loci on the B6 genetic background (25). All mouse strains
were maintained in a pathogen-free facility at Washington Uni-
versity.
 
Cell Lines. 
 
CHO cell lines (CHO as well as Lec1 and
LEC11 mutants) were a gift from Dr. P. Stanley (Albert Einstein
College of Medicine, Bronx, NY). The derivation of the mutants
has been described previously (26). All three lines were cultured
in MEM-
 
a
 
 
 
(GIBCO BRL, Gaithersburg, MD) supplemented
with ribonucleosides, deoxyribonucleosides, and 10% FCS (Har-
lan Sprague Dawley, Inc., Indianapolis, IN) without any antibiot-
ics. The BHK.vp16 hamster kidney line was provided by Dr. P.
Hippenmeyer (Monsanto, St. Louis, MO [27]). All other cell lines
were obtained from the American Type Culture Collection (Rock-
ville, MD). Cells were grown in either RPMI 1640 medium
(GIBCO BRL) supplemented with 
 
l
 
-glutamine (300 
 
m
 
g/ml), pen-
icillin (100 U/ml), streptomycin (100 
 
m
 
g/ml), 50 
 
m
 
M
 
 
 
b
 
-mercap-
toethanol, and 10% FCS or in DME (GIBCO BRL) supplemented
with 
 
l
 
-glutamine (300 
 
m
 
g/ml), penicillin (100 U/ml), strepto-
mycin (100 
 
m
 
g/ml), 50 
 
m
 
M
 
 
 
b
 
-mercaptoethanol, sodium pyruvate
(1 mM), nonessential amino acids (0.1 mM), and 10% FCS.
 
IL-2 and Antibodies.
 
Human rIL-2 was purchased from Chi-
ron Corp. (Emeryville, CA). mAbs used in this study include
GK1.5 (rat IgG2b, anti–murine CD4), J11D (rat IgM, anti–
murine B cells, neutrophils, erythrocytes, and immature thy-
mocytes), M5/114.15.2 (rat IgG, anti–MHC II), MAR 18.5
(mouse IgG2a, anti–rat 
 
k
 
 Ig), 53-6.72 (rat IgG2a, anti–murine
CD8), H57-957.1 (hamster IgG, anti–murine
 
 
 
TCR-
 
a
 
/
 
b
 
),
 
 
 
2.4G2
(rat IgG, anti–mouse
 
 
 
Fc
 
g
 
RII/III), PK136 (mouse IgG2a, anti-
NK1.1), AF6-88.5.3 (mouse IgG2a, anti–H-2K
 
b
 
), 145-2C11
(hamster IgG anti-CD3
 
e
 
), anti-2B4 (mouse IgG2b, anti-2B4),
12A8 (rat IgG2a, anti–Ly-49D and –Ly-49A), 4E5 (rat IgG, anti–
Ly-49D), 3D10 (mouse IgG1, anti–Ly-49H), and mouse IgG1
isotype control. All antibodies were either ascites preparations or
purified mAb from hybridoma culture supernatants, except for
anti-2B4 which was purchased from PharMingen (San Diego,
CA). All mAb-producing hybridomas were obtained from Amer-
ican Type Culture Collection, with the exception of 12A8 and
4E5, a gift from L. Mason and J. Ortaldo (National Cancer Insti- 
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tute, Frederick, MD), and 3D10 developed in our lab.
 
2
 
 In addi-
tion, rabbit anti-asialo ganglio-
 
N
 
-tetraosylceramide (AGM1) anti-
serum was obtained from Wako Bioproducts (Richmond, VA),
and FITC-conjugated and unconjugated goat F(ab
 
9
 
)
 
2
 
 fragments
anti–mouse Ig as well
 
 
 
as affinity-purified rabbit anti–mouse Ig
were purchased from Cappel, Inc. (Malvern, PA).
 
IL-2–activated NK Cell Preparation.
 
Splenocyte suspensions were
prepared in HBSS (GIBCO BRL) containing 10% FCS; RBCs
were lysed using Tris-buffered ammonium chloride (0.14 M
NH
 
4
 
Cl and 0.017 M Tris, pH 7.2). Washed cells were incubated
on a nylon wool column for 1 h at 37
 
8
 
C. Nylon wool nonadher-
ent cells were cultured in complete RPMI medium supple-
mented with 1,000 U/ml of rIL-2 at 2–4 
 
3 
 
10
 
6
 
 cells/ml. On day
3 or 4, adherent cells were harvested with Ca
 
2
 
1
 
/Mg
 
2
 
1
 
–free PBS
containing 0.2% EDTA (GIBCO BRL) and incubated (2 
 
3 
 
10
 
7
 
cells/ml) with the mAbs (0.5% ascites preparations) 53-6.72 and
H57-957.2 on ice in HBSS plus 3% FCS for 30 min. The cells
were washed and incubated (10
 
7
 
 cells/ml) with 10 
 
m
 
g/ml affin-
ity-purified rabbit anti–mouse Ig and 100 
 
m
 
g/ml rabbit comple-
ment (Cedarlane Labs, Inc., Westbury, NY) for 45 min at 37
 
8
 
C.
Surviving cells were separated from dead cells using a Lym-
pholyte-M density gradient (Cedarlane Labs, Inc.). These cells
were then washed and expanded for 4–6 d in culture with IL-2–
supplemented medium. Assays were performed with adherent
cells harvested on days 7–9.
 
Freshly Isolated NK Cell Preparation.
 
Mouse spleens were har-
vested and splenocyte suspensions were depleted of RBCs as de-
scribed above. Nylon wool nonadherent spleen cells (2 
 
3 
 
10
 
7
 
/
ml) were incubated with ascites preparations (0.5% final dilution)
of mAbs GK1.5, 53-6.72, J11D, and M5/114.15.2 on ice for 30
min. The cells were washed and plated onto T-75 flasks pre-
coated with goat F(ab
 
9
 
)
 
2
 
 anti–mouse Ig at 10 
 
m
 
g/ml. After 1 h at
4
 
8
 
C, the nonadherent cells were resuspended at 10
 
7
 
 cells/ml. Pu-
rified MAR 18.5 protein was added (10 
 
m
 
g/ml final) together
with rabbit complement (100 
 
m
 
g/ml final; Cedarlane Labs, Inc.)
and cells were incubated at 37
 
8
 
C for 45 min. The live cells were
rescued using a Lympholyte-M density gradient. These cells were
analyzed by FACS
 
Ò
 
 and used in cytotoxicity assays.
 
Cell Surface Expression of Molecules.
 
Cell surface markers on
IL-2–activated NK cells were evaluated using FACS
 
Ò
 
 analysis for
each cytotoxicity assay. Typical analysis examines the expression
of several cell surface molecules, including CD16 (2.4G2, rat IgG
anti-Fc
 
g
 
RII/III), 2B4 (2B4, mouse IgG anti-2B4), NK1.1
(PK136, mouse IgG anti-NK1.1),
 
 
 
and CD3
 
e
 
 (2C11, hamster IgG
anti-CD3
 
e
 
). Typically, our IL-2–activated NK cells constitute a
cell population that is 
 
.
 
90% CD3
 
2
 
CD16
 
1 
 
and 2B4
 
1
 
/
 
2
 
, NK1.1
 
1
 
/
 
2
 
(depending on the strain). Cells were incubated with saturating
concentrations of the appropriate mAbs on ice for at least 30 min.
The cells were then washed twice and incubated with FITC-con-
jugated goat F(ab
 
9
 
)
 
2
 
 anti–mouse Ig at 10 
 
m
 
g/ml final concentra-
tion. The FITC-conjugated goat F(ab
 
9
 
)
 
2
 
 anti–mouse Ig second
step reagent cross-reacts with both the rat 2.4G2 and the hamster
2C11 mAbs. Stained cells were analyzed on FACScan
 
Ò
 
 with
CellQuest
 
Ò
 
 software (Becton Dickinson, San Jose, CA). Dead
cells were excluded by propidium iodide staining.
 
Natural Killing.
 
The standard 
 
51
 
Cr-release assay was used to
establish NK lytic function. Tumor targets (2–4 
 
3 
 
10
 
6
 
) were ra-
diolabeled with 
 
51
 
Cr (50 or 100 
 
m
 
Ci) in RPMI without FCS for
90 min. Effector cells were plated onto 96-well round-bottomed
plates at various cell densities in order to achieve E/T ratios usu-
ally of 20:1, 6.7:1, and 2.2:1. Radiolabeled target cells (10
 
4 
 
cells/
well) and effectors were incubated for 4 h in a 37
 
8
 
C humidified
CO2 incubator. Subsequently, 100 ml of the supernatants was col-
lected and assayed for 51Cr release. For antibody blocking experi-
ments, mAbs were added at saturating levels to effectors and incu-
bated for 15–30 min at room temperature before the addition of
labeled target cells. The mAb 12A8 was used at 1:100 final con-
centration of an ascites preparation, and the purified mAb 4E5 at
10 mg/ml final concentration. Both the 3D10 (anti–Ly-49H) and
its isotype control were used at a final concentration of 10 mg/ml.
Specific cytotoxicity was calculated according to the standard for-
mula:
% specific lysis 5 100 3 (exp 2 spont)/(max 2 spont),
where experimental (exp) release represents the radioactivity from
the experimental wells, maximum (max) release represents counts
from detergent-lysed targets, and spontaneous (spont) release rep-
resents background release from wells with targets alone.
Lung Clearance Assay. Target cells (8 3 106) were incubated
with 50 mg of 5-fluoro-29-deoxyuridine (Sigma Chemical Co.,
St. Louis, MO) in 2 ml of complete DME for 15 min at 378C.
125I-labeled 5-iodo-29-deoxyuridine ([125I]dUrd; Amersham Phar-
macia Biotech, Inc., Piscataway, NJ) was added (5 mCi), and cells
were incubated for an additional 90–120 min at 378C. Sub-
sequently, the cells were washed in PBS. Mice were injected in-
travenously with 3 3 105 cells/200 ml PBS. 4 h after injection,
the lungs were removed, rinsed with PBS, and soaked in 70%
ethanol for at least 1 h. 125I activity in the lungs and in the inocu-
lum (200 ml) was measured using a gamma counter. Results were
determined by expressing the residual 125I activity measured in
the lungs as a percentage of the total activity in the inoculum as
follows: 
percent retention in lung 5 (average lung cpm/average inocu-
lum cpm) 3 100. 
Thus, percent retention is an indirect measure of number of sur-
viving cells in the lungs. All experiments were done with groups
of at least three mice. For in vivo NK cell depletion, 50 ml of
anti-AGM1 antiserum diluted in 200 ml vol of PBS was injected
intravenously (tail vein) 3 d before the lung clearance assay. In the
case of PK136 (anti-NK1.1) or the isotype-matched AF6-88.5.3
(anti-Kb), 100 mg of purified mAb was injected intraperitoneally
2 d before the assay.
Results
Strain-determined Differences in Natural Killing. We eval-
uated the target cell repertoires of NK cells derived from
two distinct inbred mouse strains, C57BL/6J (B6) and
BALB/cJ, to screen for genetic loci that influence NK cell
target specificity (Table 1). B6 IL-2–activated NK cells dis-
played efficient lysis of most murine tumor targets as well as
several hamster cell lines, with the exception of BB88 and
WR19L. For most targets, BALB/c-derived NK cells dis-
played a similar target specificity profile, suggesting that the
intrinsic killing capacity of BALB/c NK cells was compara-
ble to that of B6-derived effector cells. However, several
targets were killed less efficiently by BALB/c-derived NK
cells compared with B6-derived NK cells. This strain-
determined difference in capacity for target lysis was most
pronounced in killing of CHO targets as well as two vari-
ants of this line, Lec1 and LEC11. At E/T ratios .20:1, 2Smith, H.R.C., and W.M. Yokoyama, manuscript in preparation.2246 Genetic Control of NK Cells by Chok
maximal YAC-1 killing by both effector populations is ap-
parent, demonstrating that BALB/c effectors are potent
killers for sensitive targets (Fig. 1 A). Despite this, the
strain-determined difference in killing capacity of CHO
targets was maintained at E/T ratios as high as 80:1, at
which the BALB/c NK cells manifested only minimal lysis
of CHO (Fig. 1 A). Furthermore, the difference in CHO
cytotoxicity was not overcome by longer 51Cr-release as-
says. Similar differences were apparent in 4-, 8-, or 24-h as-
says (data not shown), suggesting that the observations
were not due to varying kinetics of killing. The differential
susceptibility of CHO targets was not dependent on differ-
ences in species origin of the target, since other hamster
lines, BHK (Syrian or Golden) and AHL-1 (Armenian), as
well as Chinese hamster–derived V79-4 and CHL/IU cells
were lysed equivalently by both effector populations (Table
1). Thus, compared with B6-derived effector cells, IL-2-
activated BALB/c NK cells manifest a qualitative difference
in ability to kill CHO targets.
In general, IL-2–activated NK cells display a broader tar-
get spectrum as well as higher lytic efficiency compared
with freshly isolated NK cells (1, 28, 29). Therefore, it was
possible that the differences in CHO killing were due to
differential NK cell sensitivity to activation by IL-2. How-
ever, freshly isolated B6 NK cells killed CHO, whereas
those from BALB/c did not (Fig. 1 B). Although less potent
killers, freshly isolated effectors displayed the same differen-
tial killing capacity with regard to CHO cell targets. These
results demonstrate that an intrinsic capacity unrelated to
IL-2 activation controls NK cell–mediated CHO killing.
Inheritance of Strain Difference in CHO Cell Killing and In-
dependence from Host MHC Haplotype. To characterize the
Table 1. Strain-determined Lysis of a Panel of Tumor Targets
Cell line Type n
C57BL/6J BALB/cJ
E/T ratios
20 6.7 2.2 20 6.7 2.2
Hamster Strain
CHO Fibroblast Chinese 4 76 56 29 8 3 2
Lec1 Fibroblast Chinese 1 78 69 44 9 8 6
LEC11 Fibroblast Chinese 1 86 70 54 8 8 6
V79-4 Lung Chinese 1 71 61 42 45 32 18
CHL/IU Lung Chinese 1 70 68 63 64 56 40
AHL-1 Lung Armenian 1 50 40 24 35 33 12
BHK.vp16 Kidney Syrian or Golden 1 62 59 41 68 55 32
Murine H2
YAC-1 Thymoma a 4 93 89 76 82 72 52
RAW264.7 Macrophage d 1 100 100 26 82 75 39
SP2/0 Myeloma d 1 100 93 74 90 78 56
PU51R Macrophage d 1 93 82 49 87 66 40
MPC11 Plasmacytoma d 1 56 31 19 52 31 15
MOPC315 Plasmacytoma d 1 45 26 25 43 24 30
WEHI7.1 Thymoma d 1 69 55 38 60 59 37
WR19L Lymphoma d 1 30 12 2 20 13 2
BB88 Leukemia b 1 9 1 0 15 0 0
IC-21 Macrophage b 1 89 61 37 57 36 25
B16S Melanoma b 1 71 69 28 54 54 39
BLKSVHD2 Fibroblast b 1 60 47 31 50 41 30
EL-4 Thymoma b 1 50 37 26 29 15 8
C1498 Lymphoma b 1 72 65 49 71 47 25
RMA-S Lymphoma b 1 65 50 29 48 35 20
Lysis of various tumor targets by B6- and BALB/c-derived NK cells was determined in triplicate using the standard 51Cr-release cytotoxicity assays
at E/T ratios of 20:1, 6.7:1, and 2.2:1. Tumor killing is expressed as percent specific cytotoxicity. For each target used the cell type is indicated. Ad-
ditionally, for hamster targets, the strain is specified; for murine targets, the H2 haplotype is indicated.2247 Idris et al.
inheritance pattern of this trait, cytotoxicity against CHO
cells was compared using effector cells from (BALB/c 3
B6)F1 hybrid mice and the parental strains (Fig. 2 A). Inter-
estingly, the F1 NK cells reproducibly exhibited an inter-
mediate level of cytotoxicity against the CHO target, sug-
gesting a gene dosage effect of an incomplete dominant or
codominant inheritance pattern.
Previous studies on the Ly-49A NK cell receptor indi-
cated that its expression and function are influenced by host
MHC haplotype (30–33). Since BALB/c mice are H2d
while B6 are H2b, we ascertained if CHO cell lysis is influ-
enced by host MHC haplotype by using H2 congenic
mouse strains on C57BL or BALB background. NK cells
derived from C57BL background (C57BL/10, H2b; or
B10.D2, H2d) exhibited significantly greater cytotoxicity
against CHO cells than did NK cells from H2 congenic
mouse strains with BALB/c background (BALB.B, H2b; or
BALB/c, H2d) regardless of MHC haplotype (Fig. 2 B, and
data not shown). These results argue against an influence of
the host MHC on the capacity of effector cells to lyse
CHO targets.
Panel of Inbred Mouse Strains Assessed for CHO Cytotoxicity.
We next assessed NK cells from several inbred mouse
strains to determine if this differential CHO susceptibility is
restricted to the B6 and BALB/c backgrounds (Table 2). For
each strain tested, the cytotoxicity against the prototypical
NK target, YAC-1, was determined in parallel to CHO.
Effector NK cells always retained cytolytic activity versus
YAC-1, and in no case was CHO killing more efficient
than YAC-1 killing. Since there are differences in general
capacity to mediate cytotoxicity as indicated by YAC-1
killing, we normalized for the strain differences in overall
killing efficiency by determining lysis as a ratio of CHO to
YAC-1 killing. We chose a minimum value of 0.5 as a
measure of efficient (B6-like) CHO killing for each of the
strains tested. Among the 17 additional strains examined,
only 4, C57BL/10, NZB/B1NJ, NZW/LacJ, and NOD/
LtJ, possessed NK cells that displayed CHO cytotoxic ca-
pacity similar to B6 NK cells. NK cells derived from the
remaining strains were not able to lyse CHO cells, thus dis-
playing a phenotype similar to BALB/c.
The NK1.1 and 2B4 molecules were both considered as
candidates for mediating the differential CHO lysis because
they are selectively expressed on NK cells, can activate NK
cells (18, 20, 21, 34), and exhibit strain-specific expression
on B6- but not BALB/c-derived NK cells (35–37). How-
ever, there was no correlation between expression of either
epitope by FACSÒ analysis and the capacity to lyse CHO
Figure 1. Strain-determined differences in CHO killing by NK cells.
(A) Standard chromium-release assays were performed using B6 and
BALB/c IL-2–activated NK cells (LAKs) against CHO and YAC-1 target
cells at indicated E/T ratios. (B) Cytotoxicity assays against CHO or
YAC-1 targets using freshly isolated NK cells from B6 and BALB/c.
Figure 2. Inheritance of strain difference in CHO cell killing and inde-
pendence from host MHC haplotype. (A) Lytic capacity of IL-2–acti-
vated NK cells from the (BALB/c 3 C57BL/6)F1 strain was compared
with that of parental B6 and BALB/c IL-2–activated NK cells against the
CHO and YAC-1 targets. (B) No association between H2 haplotype and
capacity to lyse CHO. IL-2–activated NK cells derived from C57BL/10,
BALB/c, and BALB.B were compared for their capacity to lyse CHO
and YAC-1 targets.2248 Genetic Control of NK Cells by Chok
(Fig. 3, and Table 2). For example, NK cells from C57L/J,
C57BR/cdJ, and C58/J strains, which express both NK1.1
and 2B4 epitopes, did not lyse CHO. Conversely, NK cells
from NOD/LtJ strain that lack expression of either epitope
displayed efficient lysis of CHO targets. Furthermore, mu-
rine NK cell clones generated in our laboratory from p53-
deficient B6 mice (16) express NK1.1 and 2B4 but do not
kill CHO cells despite efficient killing of YAC-1 targets
(data not shown). Therefore, these data show that natural
killing of CHO cell targets is not unique to the B6 strain
and cannot be correlated with expression of the NK1.1 or
2B4 antigen. These data also independently confirm that
MHC haplotype is not correlated with CHO killing.
Linkage of Chok to NKC-encoded Genes. To further charac-
terize the genetic basis for CHO cell killing, we used seven
recombinant inbred (RI) mouse strains derived from
BALB/cBy and C57BL/6By progenitor inbred strains (Fig.
4  A). Since each RI line is homozygous for either the
BALB/c or B6 allele for CHO killing, we expected to see
phenotypes that mirrored those of the progenitor strains.
Indeed, NK cells derived from CXB-1, -2, and -6 were all
B6-like (Fig. 4 B) since they lysed CHO cells efficiently.
The remaining strains, CXB-3, -4, -5 and -7, were BALB/
c-like (Fig. 4 C) and did not lyse CHO despite efficient ly-
sis of YAC-1. We observed a clear segregation of pheno-
types into high or low levels of killing, and roughly 50% of
the RI strains displayed either phenotype, consistent with
the interpretation that a single chromosomal locus deter-
mines killing of CHO targets. We have termed this locus
Chok for CHO killing.
A comparison of the strain distribution pattern (SDP) for
Chok with SDPs for other genes previously typed in the
CXB RI strains revealed complete concordance between
Chok and Ly49a, Nkrp1, and Cmv1 loci, all of which have
been mapped within the NKC on distal mouse chromo-
some 6 (Fig. 4 B). Although this analysis was limited to a
small set of RI strains, these results strongly suggest that
Chok is NKC linked.
To confirm the chromosomal location of Chok, we ex-
amined the BALB.B6-Cmv1r congenic strain that possesses
the Cmv1r allele as well as other NKC loci from B6, back-
crossed onto the BALB/c background (24). NK cells de-
rived from BALB.B6-Cmv1r mice displayed efficient lysis
against both YAC-1 and CHO cell targets (Fig. 5 A). We
Table 2. CHO Cytotoxicity and Expression of 2B4 and NK1.1 Antigens by NK Cells Derived from a Panel of Inbred Mouse Strains
Strain H2 haplotype NK1.1 expression 2B4 expression CHO percent lysis YAC-1 percent lysis CHO/YAC-1 ratio
C57BL/6J b 1155 71 0.8
C57BL/10SnJ b 1136 55 0.7
B10.D2 d 1151 70 0.7
NZB/B1NJ d 1232 36 0.9
NZW/LacJ z 1245 67 0.7
NOD/LtJ g 2245 46 1.0
BALB/cJ d 22 4 59 0.1
BALB.B b 22 5 55 0.1
DBA/2J d 2216 77 0.2
129/J b 22 6 39 0.2
C3HeB/FeJ k 22 1 58 0.0
AKR/J k 2217 69 0.2
A/J a 22 8 53 0.2
SJL/J s 22 2 30 0.1
ST/bJ k 12 1 30 0.0
CE/J k 12 4 27 0.1
C57L/J b 1110 52 0.2
C57BR/cdJ k 11 7 24 0.3
C58/J k 11 5 79 0.1
IL-2–activated NK cells derived from each indicated strain were assessed for their capacity to mediate CHO and YAC-1 lysis. Percent specific lysis
values at a 6.7:1 E/T ratio are shown in the table; similar results were obained at other E/T ratios (data not shown). To normalize for strain differ-
ences in overall killing efficiencies, the CHO/YAC-1 ratio was determined. We arbitrarily set a value for CHO/YAC-1 $ 0.5 as an index of efficient
CHO lysis. The IL-2–activated NK cells derived from each strain tested were also characterized (usually on the same day of the cytotoxicity assay)
for their expression of NK1.1 and 2B4 antigens by flow cytometric analysis.2249 Idris et al.
have recently established a reverse congenic strain, desig-
nated B6.BALB-Cmv1s, carrying the BALB/c Cmv1s allele
and other BALB/c-derived NKC loci on the B6 genetic
background (25). Consistent with the localization of Chok
to the NKC, NK cells derived from B6.BALB-Cmv1s
could not lyse CHO, indicating that these animals possess
the BALB/c allele for Chok (Fig. 5 A). These results for-
mally establish linkage of Chok to the NKC.
Figure 3. No correlation between expres-
sion of 2B4 and NK1.1 activation antigens
and capacity to lyse CHO cells. (A) IL-2–
activated NK cells from B6, BALB/cJ,
C57L/J, and NOD/LtJ were analyzed for
their capacity to lyse CHO and YAC-1 tar-
gets. (B) Flow cytometric analysis of IL-2–
activated NK cells from B6, BALB/cJ,
C57L/J, and NOD/LtJ strains. NK cells
from each of the strains were incubated
with mAbs specific for FcgRII/III (a–d),
NK1.1 (e–h), or 2B4 (i–l) followed by
FITC-conjugated goat F(ab9)2 anti–mouse
Ig. Solid lines, specific staining; dotted lines,
staining by secondary antibody alone. The
2.4G2 mAb is specific for both FcgRII and
FcgRIII, even though mouse NK cells ex-
press only FcgRIII (reference 73).
Figure 4. The SDP of CHO killing among
the CXB RI mouse strains demonstrates
linkage to the NKC. (A) IL-2–activated NK
cells derived from seven CXB RI strains as
well as the progenitor strains, C57BL/6ByJ
and BALB/cByJ, were assessed for their ca-
pacity to mediate CHO and YAC-1 lysis.
The SDP is summarized using the symbols
B and C to indicate the alleles inherited
from the C57BL/6By and BALB/cBy pro-
genitor strains, respectively. (B) Linkage of
Chok to NKC-encoded loci on chromo-
some 6. The SDP observed for the Chok lo-
cus is compared with SDPs of other genes
previously typed using the same CXB-RI
panel (references 35, 37, 47, 48, 74, and
75). The symbols B and C represent alleles
inherited from the progenitor C57BL/6By
and BALB/cBy strains, respectively.2250 Genetic Control of NK Cells by Chok
Antibodies against Ly-49D and Ly-49H Do Not Block
CHO Lysis. Since linkage of the Chok locus to the NKC
suggests that Chok may encode an NK cell recognition re-
ceptor involved in tumor killing, we evaluated this region
for genes that encode known receptors for which there are
specific monoclonal reagents. Two members of the Ly-49
family of receptors, Ly-49D and Ly-49H, lack an ITIM in
their cytoplasmic tail and have been shown to activate NK
cells (22, 38).2 To determine if either of these receptors plays
a role in CHO lysis, we examined the effect of antibodies
against these molecules in our killing assays. There are two
previously characterized anti–Ly-49D reagents: 12A8, which
also recognizes Ly-49A, and 4E5, which is monospecific for
Ly-49D (22, 39). Neither antibody had an effect on CHO
lysis by either B6 or BALB/c NK cells (Fig. 6 A). To exam-
ine the role of Ly-49H, we made use of an antibody recently
developed in our laboratory that is specific for the Ly-49H
molecule.2 Inclusion of this reagent, mAb 3D10, in our assay
also did not alter the levels of CHO lysis by B6 NK cells
(Fig. 6 B). Thus, anti–Ly-49D and anti–Ly-49H do not block
CHO killing.
Chok Regulates Rapid Elimination of CHO Cells In Vivo.
To determine if Chok could play a role in NK-mediated
activity in vivo, we performed lung clearance assays in B6
and BALB/c hosts. Intravenously inoculated 125I-radiola-
beled CHO cells were efficiently eliminated (within 4 h)
from the lungs of B6 mice as demonstrated by the low re-
sidual radioactivity measured (5 6 3%; Fig. 5 B). Treat-
ment of B6 mice with anti-AGM1 antiserum 3 d before
the assay resulted in an eightfold increase in radiolabel re-
tention, consistent with a role for NK cells in tumor clear-
ance from the lung. In contrast, untreated BALB/c mice
retained high levels of radioactivity (39 6 6%) similar to
those detected in the lungs of anti-AGM1–treated B6 mice
(41 6 4%; Fig. 5 B). In BALB/c mice, anti-AGM1 treat-
ment abolished the clearance of YAC-1 targets, but had no
effect on CHO clearance, indicating that BALB/c NK cells
were functionally intact yet incapable of recognizing the
CHO targets (data not shown, and Fig. 5 B). Thus, the in
vivo lung clearance assay results parallel the findings of the
in vitro cytotoxicity assay.
To ascertain if this strain-determined difference in CHO
elimination in vivo maps to the NKC, we compared the
lung clearance capacity of BALB/c and the congenic
BALB.B6-Cmv1r  mouse strains. CHO cells were effec-
tively eliminated in the congenic BALB.B6-Cmv1r strain
but not in BALB/c mice despite efficient clearance of
YAC-1 tumor cells in both strains (Fig. 5 C). The clear-
ance of YAC-1 and of CHO cells was abrogated in the
BALB.B6-Cmv1r mouse strain by prior injection of anti-
NK1.1 mAb but not by injection of an isotype-matched
control antibody, anti-Kb. It is noteworthy that the reten-
tion of radiolabeled CHO cell targets in the lungs of
BALB/c mice (32.5 6 6.5%) is about fivefold greater than
the level retained in the BALB.B6-Cmv1r (7.1 6 3.5%)
lungs and is very similar to the retention detected in the
lungs of NK-depleted BALB.B6-Cmv1r mice (33 6 3.4%).
These results strongly suggest that the B6 allele of Chok in
the congenic strain also plays a role in NK-mediated tumor
clearance of CHO targets in vivo.
Perforin Dependence of Chok Phenotype. In addition to the
membranolytic pathway involving granule exocytosis and
Figure 5. NK cells from
BALB.B6-Cmv1r as well as
B6.BALB-Cmv1s confirm Chok
linkage to the NKC, and Chok
regulates NK-mediated in vivo
elimination of tumor targets
through a perforin-dependent
pathway. (A) Cytotoxicity assays
against CHO and YAC-1 targets
were performed using IL-2–acti-
vated NK cells derived from B6,
BALB/c, and the NKC-con-
genic, BALB.B6-Cmv1r, and
B6.BALB-Cmv1s mouse strains.
(B)  125I-radiolabeled CHO cells
were injected into tail veins of
perforin-deficient B6, BALB/c,
or B6 mouse strains untreated or
treated with anti-AGM1 anti-
serum 3 d before the assay. Each
bar represents the mean percent
retention of six mouse lungs
except where #n 5 5. (C) Lung
clearance of [125I]UdR-labeled
YAC-1 or CHO targets was as-
sessed in BALB/c and BALB.B6-
Cmv1r congenic mice, untreated
or treated with 100 mg of either
anti-NK1.1 mAb or an isotype-
matched control anti-Kb mAb, intraperitoneally 2 d before the assay. Each bar represents the mean percent retention of four mouse lungs except where
*n 5 3. In all experiments, mice were killed and lungs were harvested 4 h after inoculation.2251 Idris et al.
release of pore-forming protein (perforin) and granzymes,
NK cells are also capable of Fas ligand–mediated cytotoxicity
(40, 41). To investigate the effector mechanisms used by B6
NK cells to kill CHO targets both in vitro and in vivo, we
made use of the perforin-deficient B6 (B6-Pfp2/2) mouse
strain. Importantly, in vitro analysis revealed that B6-Pfp2/2
NK cells could not lyse either YAC-1 or CHO in the
standard 4-h chromium-release assay (data not shown), in
agreement with previous characterization of natural killing
in these animals (42). Furthermore, we demonstrated that
the B6-Pfp2/2 mice were unable to clear the CHO cells as
reflected in the high level of radiolabel retention (35 6 4%;
Fig. 5 C). This tumor retention is very similar to that ob-
served in the B6 group treated with anti-AGM1 antiserum,
and is about sevenfold greater than in wild-type B6 mice.
Taken together, these results indicate that natural killing of
CHO targets in vitro and NK-mediated elimination of
CHO cells in vivo are perforin dependent, consistent with
differential susceptibility to NK cell recognition and subse-
quent initiation of the granule exocytosis pathway.
Discussion
In this study, we determined that the capacity of NK
cells from different strains of mice to kill CHO targets is
due to a single genetic locus, Chok. Although resistance or
susceptibility of CHO cells to NK lysis may have been due
to differences in downstream signaling events or mediators
of cytolysis, our observations strongly support a differential
recognition event. BALB/c-derived NK cells were able to
kill YAC-1 and most other targets as efficiently as B6-
derived NK cells; however, they could not lyse CHO cell
targets. Moreover, this differential capacity to kill CHO
was extended to our in vivo tumor clearance model and
was determined to be perforin dependent, suggesting that
activation of granule exocytosis was required. Therefore,
we postulate that this strain-specific cytotoxicity of CHO is
due to significant differences in NK cell specificity of target
recognition.
In support of the hypothesis that Chok encodes a pheno-
typically defined recognition structure, B6 and BALB/c
NK cells express different alleles for several target recogni-
tion molecules, including 2B4, a putative activation recep-
tor (37). Importantly, we have localized Chok to the NKC
by assessment of RI strains, a finding verified by examina-
tion of the BALB.B6-Cmv1r and the B6.BALB-Cmv1s
congenic mouse strains. The genetic analysis formally elim-
inates many known candidate genes, including 2B4. These
studies highlight the power of genetic analysis and specifi-
cally, the utility of our RI and congenic mouse strains, in
evaluation of candidate molecules in NK cell activation.
The known NKC genes encode NK receptors that have
similar structure (type II integral membrane protein orien-
tation, disulfide-linked dimers, and C-type lectin homol-
ogy) and that regulate NK cell functions. The expression of
these molecules is generally restricted to NK cells (18, 35)
and includes the mouse NKR-P1 and Ly-49 families, as
well as CD94 and NKG2, and CD69, which also have
been described in humans and rats (43–46). The NKC also
contains several other functional loci controlling NK cell
activity, including Cmv1, which determines the NK cell–
mediated clearance of MCMV, and Nka, which mediates
lymphocyte alloreactivity (47–50). Inasmuch as several of
these molecules are also known to influence NK cell speci-
ficity and recognition, we postulate that Chok encodes one
of the known NKC-encoded molecules or represents a
novel but structurally related molecule responsible for NK
cell recognition of CHO target cells.
Molecules encoded in the NKC either activate or inhibit
NK cells. With this dichotomy in mind, we propose two
alternative hypotheses to account for the strain-determined
difference in cytotoxicity against CHO. The B6-derived
NK cells may possess an activating receptor, encoded by
Chok, that interacts with the CHO target and mediates its
lysis. BALB/c mice may either lack this gene (null) or ex-
press an allele that is incapable of CHO recognition. Alter-
natively, the BALB/c allele of an inhibitory receptor may
recognize its ligand on the CHO cell, preventing NK cell
activation. In this case, B6 NK cells may either lack this re-
ceptor or possess an allelic form that is incapable of CHO
recognition. The intermediate killing of CHO targets by F1
hybrid mice provides some support for the activation re-
ceptor hypothesis, because NK cell inhibitory receptors
Figure 6. Antibodies against Ly-49D or Ly-49H do not block CHO lysis.
(A) Cytotoxicity assays against CHO targets were performed using IL-2–
activated NK cells derived from B6 and BALB/c in the presence or ab-
sence of anti–Ly-49D mAbs. (B) Neither mAb 3D10 (anti–Ly-49H) nor
the isotype control had an effect on B6 NK–mediated CHO lysis.2252 Genetic Control of NK Cells by Chok
tend to strongly dominate over NK cell activation. How-
ever, the available data do not permit unequivocal discrim-
ination between these possibilities, and it remains possible
that Chok is related to either type of NK cell receptor.
Cd69 and the Nkrp1 family of genes encode activation
receptors on rodent NK cells (20, 23). However, CD69
can be excluded as a candidate for the gene product of
Chok because it is not expressed on resting NK cells (51,
52). The Nkrp1 family includes Nkrp1c, which encodes the
most specific serologic marker of NK cells in B6 mice
(NK1.1), and which displays both strain-specific expression
and allelic polymorphism between the B6 and BALB/c
strains (36). However, there was discordance between
NK1.1 expression on NK cells and capacity to lyse CHO
targets (Table 2, and Fig. 3). Also, our B6-derived NK cell
clones, which express NK1.1, were not able to lyse CHO
targets (data not shown). Furthermore, attempts to block
CHO killing by B6 IL-2–activated NK cells using the anti-
NK1.1 mAb were not successful (data not shown). Thus,
other known genes that reside in this region may poten-
tially have a role in the Chok phenotype (e.g., the Ly-49
family).
The NKC-encoded Ly-49 family of inhibitory receptors
displays several levels of polymorphism. At least nine dis-
tinct cDNAs (A–I) have been cloned from the B6 strain,
and there is evidence implicating multiple alleles for each
Ly49 gene among inbred strains. At least three members,
Ly-49A, Ly-49C, and Ly-49G, are expressed on distinct
but overlapping NK cell subsets and are inhibitory recep-
tors specific for MHC class I molecules (53–57). In mouse
strains expressing its MHC class I ligand, Ly-49A expres-
sion is downmodulated, thus establishing a mechanism
whereby host MHC can influence the NK cell receptor
repertoire, and presumably effector function (30–32, 58,
59). The level of Ly-49A expression appears to alter the ca-
pacity of the inhibitory effect, consistent with a role for
host MHC in modulating NK cell cytotoxicity. Although
our studies of H2 congenic strains demonstrated that CHO
killing is independent of MHC haplotype, we cannot ex-
clude the possibility that an inhibitory Ly-49 molecule is
involved, since ligands for the majority of Ly-49 receptors
have not been described. Similarly, NKR-P1B contains an
ITIM and is probably inhibitory, but its ligand is not
known. Furthermore, for most of these receptors, specific
serologic reagents are not available.
On the other hand, both the Ly-49D and Ly-49H re-
ceptors lack ITIMs and can enhance NK cell lytic function
in redirected lysis assays with an anti–Ly-49D or anti–Ly-
49H mAbs (22, 38).2 However, anti–Ly-49D and anti–Ly-
49H mAbs do not affect CHO killing by B6 NK cells (Fig.
6). Nonetheless, these results do not rule out involvement
of either of these receptors, since mAbs used in our study
may not bind epitopes necessary for target recognition. Fi-
nally, recent studies have identified the mouse orthologues
of the human CD94 and NKG2 molecules. The genes for
these molecules also reside in the mouse NKC near the
Ly49 gene cluster (32), as predicted by the localization of
the human genes to a syntenic region on human chromo-
some 12p13 (60, 61). To date, however, the expression
patterns of these molecules and their functional role in NK
cell activity in mice are unknown, and specific monoclonal
reagents are lacking.
It is very possible that Chok may be the product of a
novel gene, since the mouse NKC spans at least 2.1 million
bases (50). Currently, there are cDNA cloning data on only
15 genes (9 Ly49, 3 NKRP1, CD69, NKG2D, and CD94)
of an estimated 84 genes, assuming a conservative 1 gene
per 25 kb. Thus, Chok could be the product of any one of
the aforementioned candidate known genes, or the product
of a novel gene. But whether the gene responsible for the
Chok phenotype is a known or novel gene, allelic poly-
morphism of this NKC-encoded locus affects the natural
killing of a tumor target and operates in vivo and in vitro
through a perforin-dependent mechanism. Hence, the iden-
tification of the Chok gene product will further our insight
of a known molecule or lead to the discovery of an impor-
tant and as yet unidentified molecule.
If Chok encodes a recognition structure on NK cells,
what is the nature of its putative ligand on CHO cells?
Given that some NK cell receptors encoded in the NKC,
such as Ly-49 inhibitory molecules, are known to interact
with MHC class I molecules, hamster MHC class I mole-
cules may be potential target ligands for the Chok gene
product. However, V79-4 and CHL/IU are Chinese ham-
ster cell lines that were killed efficiently by BALB/c effec-
tor populations. Since MHC polymorphism is compara-
tively limited in hamsters, it is unlikely that an MHC class I
structure represents a ligand for Chok. Moreover, given
that MHC ligands inhibit only a subset of NK cells bearing
the cognate inhibitory receptor(s), it is unlikely that CHO
cells would inhibit all BALB/c NK cells. Therefore, we
currently favor the interpretation that the differential killing
of CHO is not due to a direct inhibitory influence of target
cell MHC class I molecules.
Since many of the known molecules encoded within the
NKC are C-type lectins, it is possible that a carbohydrate
moiety expressed by CHO targets may be involved in the
interaction between CHO and NK cells. However, our
studies using glycosylation mutant variants of the parental
CHO cells strongly suggest that the ligand for Chok is
independent of complex N-linked oligosaccharides. Lec1
mutants lack demonstrable N-acetylglucosaminyltransferase
I activity and therefore have no detectable complex type
N-linked oligosaccharides, whereas the LEC11 line expresses
an a(1,3) fucosyltransferase not normally expressed by the
CHO parental cells (26). Both mutant cell lines displayed
susceptibility to B6 but not to BALB/c NK–mediated lysis,
similar to what was observed for the parental CHO targets
(Table 1). Although these results contradict studies using
human NK cells, in which a role for N-linked oligosaccha-
rides has been proposed (62–64), our data indicate that
complex N-linked carbohydrates and fucose do not affect
the susceptibility of CHO targets to lysis by murine NK
cells. These data are consistent with the hypothesis that the
product of Chok recognizes a noncarbohydrate ligand on
CHO cells.2253 Idris et al.
In addition to providing insight into the molecular basis
for specific target recognition of CHO cells, our studies
have important implications with regard to the general
phenomena of natural killing of tumor targets. We exam-
ined a large panel of tumor targets, representing different
MHC haplotypes, tissue origins, and species. Despite this,
only CHO targets manifested a dramatic difference in kill-
ing by NK cells from the two mouse strains. If Chok influ-
ences natural killing through a putative activation receptor,
and BALB/c lacks a functional Chok gene product, then
BALB/c NK cells must utilize other recognition systems,
since they can efficiently kill other targets. Therefore, on
B6 NK cells, the putative receptor that triggers CHO kill-
ing may be coexpressed with receptor systems for other tar-
gets. Any or all of such receptors could be stimulated by a
given target. Experimental strategies to dissect NK recogni-
tion that are based on a “one receptor per NK cell” model,
such as those using specific mAb blockade of a single NK
cell receptor, may be flawed because of the capacity of NK
cells to be activated through other receptor pathways. This
notion is supported by studies documenting the expression
of more than one inhibitory receptor on an NK cell and on
overlapping NK cell subsets (59). Yet, the Chok phenotype
was revealed in studies of whole populations of heteroge-
nous NK cells, indicating its dominant role in certain situa-
tions. Thus, the capacity to study the effect of a genetic lo-
cus that controls natural killing in isolation will aid in
dissection of NK cell recognition.
Finally, xenotransplantation has received considerable
interest in treating end organ failure in humans, particularly
since there is a general shortage of suitable human tissue.
The first major obstacle in xenotransplantation is hyper-
acute rejection, which is mediated by xenoreactive “natural
antibodies” and complement (65). Blockade of this hu-
moral response delays but does not abrogate rejection (65,
66). This delayed xenograft rejection is characterized by a
cellular infiltrate consisting of mainly NK cells and mac-
rophages (66, 67). Evidence is now mounting that human
NK cells are active participants in delayed xenograft rejec-
tion (68). Furthermore, other studies revealed that deple-
tion of rat NK cells led to prolonged hamster cardiac graft
survival (67). Since these experiments were performed in
the absence of xenoantibodies, they also demonstrated that
NK cells may mediate xenograft rejection via direct cyto-
toxicity. In addition to xenogeneic solid tissue transplanta-
tion, NK cells play a role in xenogeneic bone marrow
transplantation. Transplantation of rat bone marrow into
supralethally irradiated mice revealed that B6 and (B6 3
A)F1 hybrids are resistant, whereas A, BALB/c, CBA,
DBA, and C3H mice are not (69). This phenomenon,
termed xenogeneic resistance, is believed to be mediated
by radioresistant NK cells and bears many physiologic and
genetic similarities to allogeneic resistance, suggesting that
the two types of incompatibility are similar, if not identical
(70–72). Interestingly, the Chok distribution pattern among
the mouse strains tested in this study is reminiscent of that
for xenogeneic rat bone marrow rejection described above,
suggesting that these may be different manifestations of a
single mechanism. Importantly, therefore, allelic determi-
nants of NK cell reactivity against xenogeneic cells, such as
Chok, may affect xenotransplantation outcomes. Elucida-
tion of the Chok gene product and its putative ligand on
CHO target cells will provide insights into NK cell xeno-
recognition and facilitate potential clinical applications.
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